Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and rare metabolic conditions. After withdrawing its earlier ALS product following a failed confirmatory trial, it has refocused the pipeline on candidates such as avexitide for post-bariatric hypoglycemia and programs including AMX0035 in Wolfram syndrome. Its work centers on underserved indications where few approved treatments exist. Near-term activity is driven by late-stage clinical development rather than commercial sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -41.4 | — |
| Q3 2025 | 0 | — | -34.4 | — |
| Q4 2025 | 0 | — | -33 | — |
| Q1 2026 | 0 | — | -41.3 | — |
| Q2 2026 | 0 | — | -43.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Advantage Corporation (FA), Webull Corporation (BULL), Acadia Pharmaceuticals Inc. (ACAD), National Beverage Corp. (FIZZ), Xenon Pharmaceuticals Inc. (XENE), TowneBank (TOWN)